Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: The use of eDNA sampling is already well established as a tool for monitoring marine life like whales and sharks. Whenever a creature moves through its environment, it leaves behind tiny fragments of DNA from skin, scales, feathers, fur, faeces and urine. "This DNA can be captured, sequenced and then used to identify that creature by comparing the sequence obtained to large databases of known genetic sequences from hundreds of thousands of different organisms," said team spokesman Professor Neil Gemmell of the University of Otago in New Zealand. The first written record of a monster relates to the Irish monk St Columba, who is said to have banished a "water beast" to the depths of the River Ness in the 6th century. The most famous picture of Nessie, known as the "surgeon's photo", was taken in 1934 and showed a head on a long neck emerging from the water. It was revealed 60 years later to have been a hoax that used a sea monster model attached to a toy submarine. Countless unsuccessful attempts to track down the monster have been made in the years since, notably in 2003 when the BBC funded an extensive scientific search that used 600 sonar beams and satellite tracking to sweep the full length of the loch. The most recent attempt was two years ago when a high-tech marine drone found a monster - but not the one it was looking for. The discovery turned out to be replica used in the 1970 film "The Private Life of Sherlock Holmes", which sank nearly 50 years ago. Gemmell's team, which comprises scientists from Britain, Denmark, the United States, Australia and France, is keen to stress the expedition is more than just a monster hunt. "While the prospect of looking for evidence of the Loch Ness monster is the hook to this project, there is an extraordinary amount of new knowledge that we will gain from the work about organisms that inhabit Loch Ness," Gemmell said on his university website. He predicts they will document new species of life, particularly bacteria, and will provide important data on the extent of several new invasive species recently seen in the loch, such as Pacific pink salmon. Their findings are expected to be presented in January 2019.

A: Scientists plan DNA hunt for Loch Ness monster next month.
****
Q: Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Hematology (ASH). The highest trial dose was discontinued due to toxicity. Nearly a third of trial patients developed serious infections and other side effects included nerve damage and liver failure. Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration. "Based on these data, we plan to open an expanded trial," David Reese, Amgen's head of research and development, said in an interview. "We want to begin exploring quickly enrollment in earlier lines of therapy." Amgen's pipeline of bispecific antibodies, which are designed to attach to a cancer cell and an immune cell, bringing them together so the body's immune system can kill the cancer, are a cornerstone of the biotech company's oncology research. Other companies are exploring different ways to attack the same BCMA target, including bluebird bio Inc, Celgene Corp and Johnson & Johnson. Earlier at the ASH meeting, bluebird and Celgene presented early trial data showing that experimental cell therapy bb21217 induced responses in 10 out of 12 heavily pre-treated myeloma patients. Bb21217 is a next-generation version of bb2121, the companies' more advanced, but still experimental therapy in a class called CAR-T that requires harvesting a patient's own disease-fighting T-cells, modifying them in a laboratory so they target specific proteins on cancer cells and infusing them back into the patient. The manufacturing process for bb21217 is designed to improve the persistence of the altered cells. J&J, which licensed BCMA-directed CAR-T LCAR-B38M from a unit of China-based GenScript Biotech Corp, on Monday presented updated results from a Chinese study of the cell therapy in 57 previously treated myeloma patients. It showed that 88 percent of patients responded to the treatment, and 74 percent achieved remission. J&J is currently enrolling patients in an international study aimed at validating those findings. Amgen has suggested the "off the shelf" nature of its antibody platform could be an advantage from both a clinical and commercial standpoint, but oncologists say more data is needed. Trial patients are hospitalized for their first cycle of AMG420, after which they receive the drug by continuous 24-hour infusion for four weeks, followed by two weeks off therapy, for up to 10 cycles. Amgen has another BCMA-targeting antibody that lasts longer in the body, requiring less frequent infusions, but that research is at an earlier stage. In the current study, 42 patients with multiple myeloma that worsened after at least two prior treatments were given AMG420 at varying doses. A total of 13 patients responded to the treatment, including seven who achieved remission. Of the 20 patients with serious adverse events, 17 required hospitalization and four had prolonged hospitalization.

A: Amgen antibody shows promise in myeloma trial, gets FDA fast track.
****
Q: U.S. District Court Judge B. Lynn Winmill on Wednesday ordered the Forest Service to examine how exploratory drilling by British Columbia-based Otis Gold Corporation could affect groundwater and possibly fish. The company's Kilgore Project covers about 19 square miles (50 square kilometers) on Forest Service land and land managed by the state of Idaho in Clark County about 60 miles (100 kilometers) north of Idaho Falls. The company says the area contains about 825,000 ounces (23.4 million grams) of gold. The company in a summary of its plans says it would like to get the gold by digging an open-pit mine. Such a mine would require additional approval from the Forest Service. The Forest Service in August 2018 approved the expansion of the exploration part of the project that includes 10 miles (16 kilometers) of new roads and 140 drill stations. The Idaho Conservation League and the Greater Yellowstone Coalition filed the lawsuit in November 2018 contending the exploratory drilling could pollute groundwater and surface water. The groups also said the drilling would harm grizzly bears, whitebark pine, Yellowstone cutthroat trout and Columbia spotted frogs. Winmill ruled the Forest Service didn't violate environmental laws in determining the exploratory drilling wouldn't overly harm grizzly bears, whitebark pine or Columbia spotted frogs. However, Winmill found the Forest Service hadn't done an adequate analysis involving groundwater quality in the Dog Bone Ridge drainage, home to Yellowstone cutthroat trout. The trout are considered a sensitive species facing threats to its population or habitat. "The Court's ruling affirms that the Forest Service must fully assess impacts to water and sensitive species before approving mining exploration," said Laird Lucas of Advocates for the West, a legal firm that is representing the environmental groups. "There should be no doubt: Water is more precious than gold in Idaho." The U.S. Department of Justice, which defends federal agencies in lawsuits, didn't immediately respond to an inquiry from The Associated Press. Craig Lindsay, president and CEO of Otis Gold Corp., didn't immediately return a call from the AP. Otis Gold Corporation is one of two British Columbia-based companies hoping to mine for gold in Idaho with open-pit mines. The other is Midas Gold, which wants to expand two open pits and create a third in an area about 40 miles (65 kilometers) east of McCall. That area has been heavily mined for a century and Midas Gold says it will restore the area as part of its mining plan. The company's plans are in an environmental review process.

A:
Ruling puts hold on gold exploration plans in eastern Idaho.
****